Year archive

Transcenta Holding Limited — 2023 filings

All 135 regulatory filings released by Transcenta Holding Limited (6628) in 2023, sourced directly from the official regulator.

135 Filings

2023 Period

2023 filings (135)

Filing	Released	Lang
Next Day Disclosure Returns Share Issue/Capital Change	2023-12-29	English
New Arrangements on Dissemination of Corporate Communications Regulatory Filings	2023-12-28	English
GRANT OF AWARD SHARES PURSUANT TO THE SHARE INCENTIVE SCHEME Director's Dealing	2023-12-27	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON THE PUBLICATION OF PRECLINICAL RESULTS OF [177LU]LU-TST001 RADIONUCLIDE ANTIBODY CONJUGATE AS POTENTIAL NOVEL TREATMENT OPTION FOR METASTATIC GASTRIC CANCER I Regulatory Filings	2023-12-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023 Share Issue/Capital Change	2023-12-06	English
Next Day Disclosure Returns Transaction in Own Shares	2023-11-23	English
Next Day Disclosure Returns Transaction in Own Shares	2023-11-21	English
Next Day Disclosure Returns Transaction in Own Shares	2023-11-20	English
Next Day Disclosure Returns Transaction in Own Shares	2023-11-14	English
Next Day Disclosure Returns Transaction in Own Shares	2023-11-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023 Regulatory Filings	2023-11-06	English
Next Day Disclosure Returns Transaction in Own Shares	2023-11-03	English
Next Day Disclosure Returns Transaction in Own Shares	2023-11-02	English
Next Day Disclosure Returns Transaction in Own Shares	2023-11-01	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-30	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-27	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-25	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-24	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON THE UNVEILING OF UPDATED EFFICACY DATA FROM OSEMITAMAB (TST001) PLUS CAPOX AS FIRST-LINE TREATMENT FOR G/GEJ CANCER STUDY AT ESMO 2023 Regulatory Filings	2023-10-23	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-20	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-19	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-18	English
Next Day Disclosure Returns Regulatory Filings	2023-10-17	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-16	English
Next Day Disclosure Returns Regulatory Filings	2023-10-13	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-12	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-11	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-10	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-09	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-06	English
Next Day Disclosure Returns Transaction in Own Shares	2023-10-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023 Regulatory Filings	2023-10-05	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON THE RECEIVAL OF CLEARANCE FROM FDA TO PROCEED WITH GLOBAL PHASE III TRIAL OF OSEMITAMAB (TST001) AS FIRST-LINE TREATMENT FOR GASTRIC/GASTROESOPHAGEAL CAN Regulatory Filings	2023-10-04	English
Next Day Disclosure Returns Share Issue/Capital Change	2023-09-29	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-28	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-27	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-25	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-21	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-20	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-19	English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS Report Publication Announcement	2023-09-15	English
2023 INTERIM REPORT Interim / Quarterly Report	2023-09-15	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-11	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-07	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-06	English
Next Day Disclosure Returns Transaction in Own Shares	2023-09-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023 Share Issue/Capital Change	2023-09-05	English
Next Day Disclosure Returns Transaction in Own Shares	2023-08-31	English
Next Day Disclosure Returns Transaction in Own Shares	2023-08-30	English
Next Day Disclosure Returns Transaction in Own Shares	2023-08-23	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2023-08-23	English
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES Board/Management Information	2023-08-22	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023 Interim / Quarterly Report	2023-08-22	English
DATE OF BOARD MEETING Regulatory Filings	2023-08-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023 Regulatory Filings	2023-08-04	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON THE RECEIVAL OF APPROVAL FROM CHINA CDE FOR THE COMPANY'S ANTI-SCLEROSTIN MONOCLONAL ANTIBODY TST002 (BLOSOZUMAB) TO INITIATE PHASE II CLINICAL TRIAL IN Regulatory Filings	2023-07-31	English
GRANT OF AWARD SHARES PURSUANT TO THE SHARE INCENTIVE SCHEME Regulatory Filings	2023-07-21	English
Next Day Disclosure Returns Share Issue/Capital Change	2023-07-21	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON APPROVALS FROM CHINA CDE AND SOUTH KOREA MFDS TO INITIATE TRANSTAR 301 GLOBAL PHASE III PIVOTAL TRIAL OF OSEMITAMAB (TST001) Regulatory Filings	2023-07-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023 Regulatory Filings	2023-07-06	English
Next Day Disclosure Returns Share Issue/Capital Change	2023-06-30	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON PRESENTATION OF EFFICACY DATA OF OSEMITAMAB (TST001) PLUS CAPOX AT 2023 ESMO GI ANNUAL CONGRESS Regulatory Filings	2023-06-30	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-20	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-19	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-16	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-15	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-14	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-13	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-12	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-09	English
AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION Governance Information	2023-06-09	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, JUNE 9, 2023 Declaration of Voting Results & Voting Rights Announcements	2023-06-09	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-08	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023 Regulatory Filings	2023-06-06	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON PRESENTATION OF UPDATED DATA OF OSEMITAMAB (TST001) IN COMBINATION WITH CAPOX AS A FIRST-LINE TREATMENT OF G/GEJ CANCER AT 2023 ASCO ANNUAL MEETING Regulatory Filings	2023-06-06	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-05	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-02	English
Next Day Disclosure Return Transaction in Own Shares	2023-06-01	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-31	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-30	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-29	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-25	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-24	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-23	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-19	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-18	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON ENCOURAGING PHASE I CLINICAL DATA OF TST002 (BLOSOZUMAB) IN CHINESE PATIENTS WITH REDUCED BONE MINERAL DENSITY Regulatory Filings	2023-05-17	English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS Report Publication Announcement	2023-05-16	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2023-05-16	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 9, 2023 AGM Information	2023-05-16	English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND PROPOSED ADOPTION OF NEW MEMORANDUM AND ARTICLES OF ASSOCIATION AND GR AGM Information	2023-05-16	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-15	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-12	English
Next Day Disclosure Return Transaction in Own Shares	2023-05-11	English
(Revised) Next Day Disclosure Return Transaction in Own Shares	2023-05-11	English
Next Day Disclosure Returns Transaction in Own Shares	2023-05-10	English
PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY Regulatory Filings	2023-05-09	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON COMPANY'S PRESENTATION OF TWO CLINICAL TRIAL PROGRESS AT ASCO 2023 Regulatory Filings	2023-05-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023 Regulatory Filings	2023-05-05	English
Next Day Disclosure Returns Transaction in Own Shares	2023-05-03	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON COMPLETION OF ENROLLMENT IN COHORTS C AND G OF CHINA PHASE II CLINICAL STUDY OF OSEMITAMAB (TST001) IN COMBINATION WITH CAPOX WITH OR WITHOUT NIVOLUMAB AS FIR Regulatory Filings	2023-05-03	English
Next Day Disclosure Returns Transaction in Own Shares	2023-05-02	English
NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED HOLDERS Report Publication Announcement	2023-04-27	English
2022 Environmental, Social and Governance Report Environmental & Social Information	2023-04-27	English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS Report Publication Announcement	2023-04-27	English
2022 ANNUAL REPORT Annual Report	2023-04-27	English
Next Day Disclosure Returns Transaction in Own Shares	2023-04-25	English
Next Day Disclosure Returns Transaction in Own Shares	2023-04-21	English
Next Day Disclosure Returns Transaction in Own Shares	2023-04-20	English
Next Day Disclosure Returns Transaction in Own Shares	2023-04-19	English
Next Day Disclosure Returns Transaction in Own Shares	2023-04-18	English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023 Regulatory Filings	2023-04-13	English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023 Regulatory Filings	2023-04-13	English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022 Regulatory Filings	2023-04-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023 Regulatory Filings	2023-04-11	English
GRANT OF AWARD SHARES AND OPTIONS PURSUANT TO THE SHARE INCENTIVE SCHEME Director's Dealing	2023-04-06	English
GRANT OF AWARD SHARES AND OPTIONS PURSUANT TO THE SHARE INCENTIVE SCHEME Regulatory Filings	2023-03-31	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022 AND CHANGE IN USE OF PROCEEDS Annual Report	2023-03-30	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON COMPANY'S OSEMITAMAB(TST001) TARGETING CLAUDIN18.2 BEING GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF PANCREATIC CANCER Regulatory Filings	2023-03-29	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON COMPANY'S PRESENTATION OF TWO PRECLINICAL STUDIES AT AACR 2023 Regulatory Filings	2023-03-23	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON FIRST PATIENT DOSED IN THE U.S. STUDY OF ITS FIRST-IN-CLASS GREMLIN1 TARGETING ANTIBODY TST003 FOR THE TREATMENT OF SOLID TUMORS Regulatory Filings	2023-03-23	English
DATE OF BOARD MEETING Regulatory Filings	2023-03-13	English
POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON THURSDAY, 9 MARCH 2023 Declaration of Voting Results & Voting Rights Announcements	2023-03-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023 Regulatory Filings	2023-03-06	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON RESULTS OF CLDN18.2-TARGETING IMMUNO-PET PROBE FOR NON-INVASIVE IMAGING IN GASTROINTESTINAL TUMORS Regulatory Filings	2023-03-03	English
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS Report Publication Announcement	2023-02-16	English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, MARCH 9, 2023 Proxy Solicitation & Information Statement	2023-02-16	English
NOTICE OF EXTRAORDINARY GENERAL MEETING Regulatory Filings	2023-02-16	English
(1) GRANT OF RESTRICTED SHARE UNITS (2) GRANT OF AWARD SHARES AND OPTIONS AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2023-02-16	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023 Regulatory Filings	2023-02-06	English
Next Day Disclosure Returns Share Issue/Capital Change	2023-02-02	English
CLARIFICATIONS REGARDING THE GRANT OF RESTRICTED SHARE UNITS IN DECEMBER 2022 AND GRANT OF AWARD SHARES AND OPTIONS Share Issue/Capital Change	2023-01-26	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022 Share Issue/Capital Change	2023-01-09	English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON IND CLEARANCE FROM NMPA FOR ITS FIRST-IN-CLASS GREMLIN1 TARGETING ANTIBODY TST003 FOR THE TREATMENT OF SOLID TUMORS Capital/Financing Update	2023-01-03	English